- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03057327
Promoting Early Detection of Melanoma During the Mammography Experience
The proposed study is a pilot and feasibility study designed to develop materials to enhance early detection of melanomas among women at risk to develop melanoma due to indoor tanning, having a family history of melanoma or a personal history of melanoma.
The hypothesis of this study is that women, who are engaged in health promotion by having mammograms, will be able to assess the personal relevance of skin self-examination (SSE), be interested in learning about SSE and able to implement SSE while they are partially disrobed in the privacy of the changing room in the mammogram facility.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After patients complete the mammogram, they return to the changing room and put on their clothing. After exiting the changing room in the Lynn Sage Comprehensive Breast Center of Northwestern Medicine/Prentice Women's Hospital and as they are preparing to leave, a research assistant (RA) will screen potential participants to acquire a randomly selected convenience sample of eligible participants (n=200). The first 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next. Verbal assent will be obtained.
Then the SSE materials will be placed into the changing rooms and the next 100 eligible subjects will be surveyed. The women, who found the information relevant, will be asked if they chose to check their skin while in the changing room. The skin location checked and use of the SSE kit will be ascertained. Women will be asked if they think they have a concerning mole. If the woman does not find a concerning mole, she will be asked if she intends to check her skin again. In addition, she will be asked if she intends to check the skin of family members. Women will be invited to take a brochure to help implement SSE.
The screening questions are as follows:
During your visit for mammography, did you notice any information about checking your skin for melanoma?
___Yes __ No
- Did you think this applied to you? ___Yes __ No
- If no, why not? (open ended)
- If yes, why? (open ended)
Did you check your skin? (If no, please proceed to question #8)
___Yes __ No
If yes, did you notice any concerning moles?
- Yes __ No
If yes, may we contact you by telephone or email in 2 weeks to see if you have made an appointment to see a dermatologist?
___Yes __ No If yes, which way do you prefer to be contacted?
Phone _________________________(Number) Email _________________________ (Address)
If no, will you consider checking your skin in the future?
___Yes __ No
If yes, may we contact you by telephone or email in 2 weeks to see if you have checked your skin for any concerning moles?
___Yes __ No If yes, which way do you prefer to be contacted?
Phone _________________________(Number) Email _________________________ (Address)
If you found any concerning moles, did you make an appointment to see a dermatologist.
- Yes __ No
The RA will record the responses. Women who checked their skin ,either today or in about 2 weeks, will be invited to participate in a survey about skin location(s) checked, use of the SSE kit, and their decision about the spot on the skin.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Qualitative research: structured interview Women 18 years of age and older, who are waiting to have a mammogram Women agree to a structured interview regarding knowledge of melanoma and awareness of melanoma risk.
Following development of a draft of a brochure, women will agree to review a draft and provide comment during a 5 minute interview
- Qualitative research: focus group Women 18 years of age and older Women with a history of regular mammograms Women with a history of indoor tanning, a personal history of skin cancer, and/or a family history of skin cancer Women willing to participate in a 60 minute focus group to assess materials to be provided during the mammogram experience
- Quantitative research
Women 18 years of age and older who respond positively to the three screening questions:
Noticed information about checking your skin for melanoma. Thought this information was applicable to them. Checked skin or will consider checking skin in the future.
Exclusion Criteria:
- Women who are unable to see to read a newspaper, unable to read English, and who have cognitive impairment causing problems with functioning at a sixth grade reading level or inability to speak.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: comparator
As women exit the changing are they will be asked if they regularly check their skin for concerning moles
|
Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features.
If the response is yes, then they will be asked if they have found concerning moles and what they did next.
|
|
Experimental: Improve awareness of checking moles
Posters, brochures, and skin self-examination kits consisting of a ruler, and a lighted magnifying lens will be placed into each of the 8 changing rooms in the mammogram facility.
|
Intervention:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance of SSE
Time Frame: 4 weeks
|
Checked Moles
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Questionnaire to identify concerning moles
Time Frame: 2 weeks
|
Found Concerning mole
|
2 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Management of decision
Time Frame: 2 weeks
|
Made appointment to see a doctor about the mole
|
2 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00204685
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma (Skin Cancer)
-
Skin Analytics LimitedInnovate UKCompleted
-
Apexigen America, Inc.TerminatedMelanoma | Cancer | Metastatic Melanoma | Melanoma (Skin) | Unresectable Melanoma | Cancer of SkinSpain, Poland
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeRecruitingNon-Melanoma Skin Cancer (NMSC) | Benign Skin GrowthUnited States
-
University of PennsylvaniaUniversity of Missouri-Columbia; Oregon Health and Science University; Stanford... and other collaboratorsCompletedSkin Cancer, Non-Melanoma | Mohs Micrographic Surgery | Skin Cancer MelanomaUnited States
-
Universitaire Ziekenhuizen KU LeuvenRecruitingSkin Cancer, Non-Melanoma | Skin Cancer MelanomaBelgium
-
Oncovir, Inc.National Cancer Institute (NCI); University of Missouri-Columbia; Icahn School... and other collaboratorsCompletedMelanoma | Sarcoma | Head and Neck Cancer | Non-Melanoma Skin CancersUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
Linnaeus Therapeutics, Inc.Merck Sharp & Dohme LLCRecruitingUnresectable Melanoma | Cutaneous Melanoma | Melanoma (Skin Cancer) | Melanoma Stage IIIB-IVUnited States
-
Iovance Biotherapeutics, Inc.Active, not recruitingMetastatic Melanoma | Unresectable Melanoma | Melanoma (Skin Cancer)United States, United Kingdom, Australia, Canada
-
Assiut UniversityNot yet recruitingNon-melanoma Skin Cancer
Clinical Trials on Comparator
-
National University of SingaporeActive, not recruiting
-
Eisai Inc.CompletedAlzheimer's DiseaseUnited States
-
Merck Sharp & Dohme LLCTerminated
-
TiumBio Co., Ltd.CompletedEndometriosisUkraine, Russian Federation, Italy, Czechia, Poland
-
Merck Sharp & Dohme LLCWithdrawn
-
Merck Sharp & Dohme LLCTerminatedType 2 Diabetes
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCTerminated
-
Cognition TherapeuticsTerminatedAge-Related Macular DegenerationUnited States